Published in Expert Rev Vaccines on October 01, 2007
Programming the magnitude and persistence of antibody responses with innate immunity. Nature (2011) 5.18
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol (2010) 4.06
Physical approaches to biomaterial design. Nat Mater (2009) 4.01
Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway. Nat Immunol (2008) 3.43
Toll-like receptor 2-dependent induction of vitamin A-metabolizing enzymes in dendritic cells promotes T regulatory responses and inhibits autoimmunity. Nat Med (2009) 2.30
Engineering nano- and microparticles to tune immunity. Adv Mater (2012) 1.75
Delivery of foreign antigens by engineered outer membrane vesicle vaccines. Proc Natl Acad Sci U S A (2010) 1.43
Strong antibody responses induced by protein antigens conjugated onto the surface of lecithin-based nanoparticles. J Control Release (2009) 1.20
Microparticle surface modifications targeting dendritic cells for non-activating applications. Biomaterials (2012) 0.99
Bacterial polyester inclusions engineered to display vaccine candidate antigens for use as a novel class of safe and efficient vaccine delivery agents. Appl Environ Microbiol (2009) 0.98
Electrostatic surface modifications to improve gene delivery. Expert Opin Drug Deliv (2010) 0.94
The effect of antigen encapsulation in chitosan particles on uptake, activation and presentation by antigen presenting cells. Biomaterials (2012) 0.92
Size mapping of electric field-assisted production of polycaprolactone particles. J R Soc Interface (2010) 0.89
Vaccines displaying mycobacterial proteins on biopolyester beads stimulate cellular immunity and induce protection against tuberculosis. Clin Vaccine Immunol (2011) 0.89
Multifunctional dendritic cell-targeting polymeric microparticles: engineering new vaccines for type 1 diabetes. Hum Vaccin (2011) 0.89
Towards preserving the immunogenicity of protein antigens carried by nanoparticles while avoiding the cold chain. Int J Pharm (2010) 0.88
Beyond antigens and adjuvants: formulating future vaccines. J Clin Invest (2016) 0.87
Self-assembling protein nanoparticles in the design of vaccines. Comput Struct Biotechnol J (2015) 0.87
Targeting the tumor microenvironment with anti-neu/anti-CD40 conjugated nanoparticles for the induction of antitumor immune responses. Vaccine (2009) 0.85
Mechanistic insight into the TH1-biased immune response to recombinant subunit vaccines delivered by probiotic bacteria-derived outer membrane vesicles. PLoS One (2014) 0.84
Coincorporation of LpxL1 and PagL mutant lipopolysaccharides into liposomes with Neisseria meningitidis opacity protein: influence on endotoxic and adjuvant activity. Clin Vaccine Immunol (2010) 0.82
Combinatorial delivery of immunosuppressive factors to dendritic cells using dual-sized microspheres. J Mater Chem B Mater Biol Med (2014) 0.82
A polysaccharide isolated from Agaricus blazei Murill (ABP-AW1) as a potential Th1 immunity-stimulating adjuvant. Oncol Lett (2013) 0.81
Non-carrier nanoparticles adjuvant modular protein vaccine in a particle-dependent manner. PLoS One (2015) 0.80
Outer membrane vesicles as platform vaccine technology. Biotechnol J (2015) 0.80
The nanomaterial-dependent modulation of dendritic cells and its potential influence on therapeutic immunosuppression in lupus. Biomaterials (2013) 0.79
Functionalization of immunostimulating complexes (ISCOMs) with lipid vinyl sulfones and their application in immunological techniques and therapy. Int J Nanomedicine (2012) 0.79
Applications of nanomaterials as vaccine adjuvants. Hum Vaccin Immunother (2014) 0.79
Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodies. Vaccine (2011) 0.78
Protective T Cell and Antibody Immune Responses against Hepatitis C Virus Achieved Using a Biopolyester-Bead-Based Vaccine Delivery System. Clin Vaccine Immunol (2016) 0.78
In vitro perforation of human epithelial carcinoma cell with antibody-conjugated biodegradable microspheres illuminated by a single 80 femtosecond near-infrared laser pulse. Int J Nanomedicine (2012) 0.78
Nucleic acid-mediated intracellular protein delivery by lipid-like nanoparticles. Biomaterials (2014) 0.77
Whole Pichia pastoris yeast expressing measles virus nucleoprotein as a production and delivery system to multimerize Plasmodium antigens. PLoS One (2014) 0.77
Antigen vehiculization particles based on the Z protein of Junin virus. BMC Biotechnol (2012) 0.77
Nanotoxoid Vaccines. Nano Today (2014) 0.77
CD40mAb adjuvant induces a rapid antibody response that may be beneficial in post-exposure prophylaxis. J Immune Based Ther Vaccines (2010) 0.77
Polymeric Materials for Gene Delivery and DNA Vaccination. Adv Mater (2008) 0.76
Particle based vaccine formulations for transcutaneous immunization. Hum Vaccin Immunother (2013) 0.76
Testicular biodistribution of 450 nm fluorescent latex particles after intramuscular injection in mice. Biomed Microdevices (2013) 0.76
Second international congress on immunopharmacology: delivery systems and current strategies for drug design. BMC Immunol (2013) 0.75
Preparation and immunogenicity of influenza virus-like particles using nitrocellulose membrane filtration. Clin Exp Vaccine Res (2017) 0.75
Employing Escherichia coli-derived outer membrane vesicles as an antigen delivery platform elicits protective immunity against Acinetobacter baumannii infection. Sci Rep (2016) 0.75
Cubosome nanoparticles potentiate immune properties of immunostimulants. Int J Nanomedicine (2016) 0.75
Toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy. Int J Nanomedicine (2016) 0.75
Engineered Human Ferritin Nanoparticles for Direct Delivery of Tumor Antigens to Lymph Node and Cancer Immunotherapy. Sci Rep (2016) 0.75
Systemic antibody response to nano-size calcium phospate biocompatible adjuvant adsorbed HEV-71 killed vaccine. Clin Exp Vaccine Res (2015) 0.75
Nanodiamond enhances immune responses in mice against recombinant HA/H7N9 protein. J Nanobiotechnology (2017) 0.75
Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine (2004) 1.74
Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines. Immunol Cell Biol (2004) 1.02
Characterization of human immunodeficiency virus Gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles. J Virol (2005) 1.00
Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations. Immunology (2003) 0.94
A comparison of anionic nanoparticles and microparticles as vaccine delivery systems. Hum Vaccin (2007) 0.89
A practical approach to the use of nanoparticles for vaccine delivery. J Pharm Sci (2006) 0.88
Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice. PLoS Curr (2009) 0.86
A vaccination strategy to enhance mucosal and systemic antibody and T cell responses against influenza. Clin Immunol (2007) 0.84
Plasmid DNA encoding human carcinoembryonic antigen (CEA) adsorbed onto cationic microparticles induces protective immunity against colon cancer in CEA-transgenic mice. Vaccine (2003) 0.82
Polylactide-co-glycolide (PLG) microparticles modify the immune response to DNA vaccination. Vaccine (2007) 0.80
Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88. Antiviral Res (2008) 0.78
A modified process for preparing cationic polylactide-co-glycolide microparticles with adsorbed DNA. Int J Pharm (2006) 0.77
Preparation of highly concentrated influenza vaccine for use in novel delivery approaches. J Pharm Sci (2013) 0.76
Intranasal immunization with influenza vaccine and a detoxified mutant of heat labile enterotoxin from Escherichia coli (LTK63). J Control Release (2002) 0.76